(Total Views: 910)
Posted On: 05/04/2022 4:46:44 PM
Post# of 148899
With regard to potential partnership opportunities, look at this disclosure by Dr. Noureddin near the end of the article published 2/26/22 that I linked below:
Dr. Noureddin owns stock in and received grants from Viking. He advises and received grants from Gilead, Madrigal, and Pfizer. He consults for Perspectum. He advises 89 Bio, Altimmune, CohBar, Cytodyn, Intercept, Novo Nordisk, Blade, EchoSens, Fractyl, NorthSea, Terns, Siemens, and Roche. He received grants from Allergan, BMS, Galmed, Galectin, Genfit, Conatus, Enanta, Novartis, Shire, and Zydus. He owns stock in Anaetos and Rivus Pharma.
https://aasldpubs.onlinelibrary.wiley.com/doi.../hep.32427
Someone asked recently when Dr. Noureddin joined the Scientific Advisory Board. This is from a PR on 9/1/2020:
CytoDyn Inc. (OTC.QB: CYDY), "CytoDyn" or the "Company", a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced the formation and initial members of its Scientific Advisory Board today including leading HIV, NASH, Oncology, and Rheumatological clinical experts and researchers.
CytoDyn's Scientific Advisory Board members include Dr. Gero Hütter, German hematologist, best known for the bone marrow transplant resulting in the cure of the first HIV patient; Dr. Hope S. Rugo, Professor, Department of Medicine (Hematology/Oncology) and Director of the Breast Oncology Clinical Trials Education Program at University of California San Francisco; Dr. Richard T. Maziarz, Professor, Medical Director of the Adult Blood and Marrow Stem Cell Transplant and Cellular Therapy Program Knight Cancer Institute at Oregon Health & Science University (OHSU); Dr. Jonah B. Sacha, Professor, VGTI-Vaccine and Gene Therapy Institute at OHSU; Dr. Mazen Noureddin, a hepatologist and Director, Cedars-Sinai Liver Transplant Program in Los Angeles; Dr. Norman B. Gaylis, nationally and internationally recognized specialist in rheumatology and autoimmune diseases; Dr. Eric D. Mininberg, Oncology Specialist, Piedmont Cancer Institute, a member of the MD Anderson Cancer Network; and Dr. Lishomwa Ndhlovu, Assistant Professor, Immunology, Department of Medicine, Division of Infectious Disease at Weill Cornell Medicine in New York.
Dr. Noureddin owns stock in and received grants from Viking. He advises and received grants from Gilead, Madrigal, and Pfizer. He consults for Perspectum. He advises 89 Bio, Altimmune, CohBar, Cytodyn, Intercept, Novo Nordisk, Blade, EchoSens, Fractyl, NorthSea, Terns, Siemens, and Roche. He received grants from Allergan, BMS, Galmed, Galectin, Genfit, Conatus, Enanta, Novartis, Shire, and Zydus. He owns stock in Anaetos and Rivus Pharma.
https://aasldpubs.onlinelibrary.wiley.com/doi.../hep.32427
Someone asked recently when Dr. Noureddin joined the Scientific Advisory Board. This is from a PR on 9/1/2020:
CytoDyn Inc. (OTC.QB: CYDY), "CytoDyn" or the "Company", a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced the formation and initial members of its Scientific Advisory Board today including leading HIV, NASH, Oncology, and Rheumatological clinical experts and researchers.
CytoDyn's Scientific Advisory Board members include Dr. Gero Hütter, German hematologist, best known for the bone marrow transplant resulting in the cure of the first HIV patient; Dr. Hope S. Rugo, Professor, Department of Medicine (Hematology/Oncology) and Director of the Breast Oncology Clinical Trials Education Program at University of California San Francisco; Dr. Richard T. Maziarz, Professor, Medical Director of the Adult Blood and Marrow Stem Cell Transplant and Cellular Therapy Program Knight Cancer Institute at Oregon Health & Science University (OHSU); Dr. Jonah B. Sacha, Professor, VGTI-Vaccine and Gene Therapy Institute at OHSU; Dr. Mazen Noureddin, a hepatologist and Director, Cedars-Sinai Liver Transplant Program in Los Angeles; Dr. Norman B. Gaylis, nationally and internationally recognized specialist in rheumatology and autoimmune diseases; Dr. Eric D. Mininberg, Oncology Specialist, Piedmont Cancer Institute, a member of the MD Anderson Cancer Network; and Dr. Lishomwa Ndhlovu, Assistant Professor, Immunology, Department of Medicine, Division of Infectious Disease at Weill Cornell Medicine in New York.
(7)
(0)Scroll down for more posts ▼
